Following the 32nd International Epilepsy Congress in Barcelona, Spain, news reports covering the event highlighted the potential CBD holds in the treatment of epilepsy.
Held from September 2-6, the International Epilepsy Congress gathered attendees together to share the latest developments in our understanding of epilepsy, featuring presentations and panel discussions by some of the most respected minds in the field of neuroscience and epilepsy.
Among the new studies discussed at the event was Dr. Saul Garza’s groundbreaking research into the use of CBD oil to treat patients with epilepsy. On the second day of the event, Dr. Garza presented his recent study using RSHO-X™, a THC-free CBD oil, as a method of treatment for Lennox-Gastaut Syndrome (LGS), a severe form of pediatric epilepsy.
In the 39 patients who participated in the study, an 84% average reduction in motor seizures were experienced; 53% of patients reported better than a 75% reduction in seizures; and 17% reported a complete elimination of all seizures over a 4-month period. The study also reported an increased quality of life in all patients who participated.
Results like those found in Dr. Garza’s study have made CBD a central topic at events like the International Epilepsy Congress in Barcelona. There is a growing desire for CBD oil that is driving a cultural shift in the perception of cannabinoids and their therapeutic potential in Spain, the EU, and around the world.
Dr. Garza’s study was conducted out of Mexico, where THC-free CBD products have been legal since 2016 with a doctor’s prescription and government approval. Soon after the legalization of THC-free products, social pressure and a shift in policy led to the passing of medical marijuana in Mexico. Now, products containing up to 1 percent THC can be prescribed by a doctor and legally used as a method of treatment for a range of conditions.
International media and local Spanish news sources alike featured the event, focusing on Dr. Garza’s study and the impact the therapeutic use of hemp-derived CBD has had in the treatment of refractory epilepsy. Stories in a number of outlets, like La Vanguardia, Heraldo Spain, ABC Spain, and El Economista, centered on the results of Dr. Garza’s work, demonstrating CBD’s potential as a treatment option for suffering patients.
Additional coverage of the 32nd International Epilepsy Congress and Dr. Garza’s study can be found in these sources and more:
Discover additional updates about RSHO-X™and its therapeutic use in Mexico on our news feed.